晚期NSCLC-EGFR TKIs耐药后治疗策略
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/587015593_small.jpgEGFR TKIs获得性抵抗三维模型-17
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/789518813_small.jpg
4项研究结论相似-32
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/146559125_small.jpg
2013年3月第十届中国肺癌高峰论坛部分共识-34
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/571043671_small.jpg
EGFR TKI获得性抵抗的管理-31
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/401174325_small.jpg
EGFR TKI抵抗-10
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/395533028_small.jpg
EGFR-TKI一线治疗EGFR突变的NSCLC-3
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/138662422_small.jpg
EGFR突变-5
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/604063572_small.jpg
Gefitinib+INC280-12
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/141195460_small.jpg
gefitinib化疗-13
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/812854215_small.jpg
MetMAb联合erlotinib-11
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/804488390_small.jpg
OS-19
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/195227774_small.jpg
PPS-18
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/776652945_small.jpg
TKI耐药后重复活检，寻找耐药机制-8
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/120088313_small.jpg
从TKI失败算起的生存期-25
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/468309000_small.jpg
从确诊算起的生存期-26
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/702513981_small.jpg
定义-4
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/35045367_small.jpg
根据耐药模式决定后续治疗策略-21
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/957237741_small.jpg
缓慢进展型OS-20
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/992720305_small.jpg
根据EGFR突变状态-27
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/957975093_small.jpg
局部治疗手段-29
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/452477781_small.jpg
获得性抵抗的机制-6
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/91234627_small.jpg
局部治疗手段的生存期TTP、OS-30
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/803286325_small.jpg
来自Memorial Sloan-Kettering Cancer Center-28
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/260975492_small.jpg
临床主要获得性抵抗机制-7
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/157473652_small.jpg
来自德国的病例对照研究-24
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/596747308_small.jpg
来自日本的研究-22
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/833457223_small.jpg
内容提要-2
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/989774668_small.jpg
日常临床实践-15
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/700561679_small.jpg
晚期NSCLC-EGFR TKIs耐药后治疗策略-1
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/148537031_small.jpg
晚期非小细胞肺癌EGFR-TKI临床失败模式与后续管理-16
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/328536058_small.jpg
一线治疗开始算起的survival time-23
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/931964202_small.jpg
谢谢-36
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/441358910_small.jpg
展望-33
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/818180612_small.jpg
总结-35
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/99019257_small.jpg
针对耐药突变设计临床试验-9
http://img.dxycdn.com/cms/upload/userfiles/image/2013/12/16/934032967_small.jpg
正在进行中的研究-14
太复杂了吧。我帖子里8楼有张图，很清晰
http://www.yuaigongwu.com/thread-12723-1-1.html
页:
[1]